SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Syndax Pharmaceuticals Inc (SNDX) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has shown impressive revenue growth in Q4 2025, its consistent net losses, missed EPS expectations, and lack of clear technical or proprietary trading signals suggest that it may not be the best entry point for long-term investment at this time.
The MACD is negative and contracting, RSI is neutral at 53.662, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 20.574, with key resistance at 21.482 and support at 19.667. Overall, technical indicators suggest a neutral trend.
Q4 2025 revenue surged 794.9% YoY, driven by strong performance of Revuforj.
Analysts maintain a Buy rating with a raised price target to $28, indicating confidence in future growth.
Q4 2025 net loss of $68.01 million and missed EPS expectations (-$0.78 vs -$0.58 estimated).
Pre-market price is down 1.11%, reflecting negative sentiment.
No significant insider or hedge fund activity, and no recent congress trading data.
Syndax Pharmaceuticals reported Q4 2025 revenue of $68.7 million, a 794.5% YoY increase, but continues to post significant net losses (-$68.01 million in Q4). Gross margin remains high but has slightly declined, and EPS continues to underperform.
BofA analyst Jason Zemansky raised the price target to $28 from $27 and reiterated a Buy rating. Analysts are optimistic about the company's future growth potential despite short-term challenges.
